Tempus AI, Inc. (NASDAQ:TEM) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Tempus AI, Inc. (NASDAQ:TEM) have been assigned an average rating of “Moderate Buy” from the thirteen analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $79.3077.

A number of research firms have commented on TEM. Stifel Nicolaus set a $60.00 price target on Tempus AI in a research note on Wednesday. Needham & Company LLC lowered their target price on shares of Tempus AI from $100.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday. Piper Sandler lowered their target price on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a report on Tuesday, November 11th. Canaccord Genuity Group cut their price target on Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, December 22nd. Finally, Robert W. Baird began coverage on Tempus AI in a report on Tuesday, February 17th. They set an “outperform” rating and a $59.00 price target on the stock.

Insider Buying and Selling

In other Tempus AI news, EVP Andrew Polovin sold 10,949 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $60.31, for a total transaction of $660,334.19. Following the transaction, the executive vice president owned 126,918 shares in the company, valued at approximately $7,654,424.58. The trade was a 7.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Erik Phelps sold 9,464 shares of the firm’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $59.43, for a total value of $562,445.52. Following the completion of the sale, the executive vice president directly owned 79,816 shares of the company’s stock, valued at approximately $4,743,464.88. This trade represents a 10.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 596,035 shares of company stock worth $37,505,125 in the last three months. Company insiders own 26.27% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Renaissance Capital LLC lifted its position in shares of Tempus AI by 26.9% in the 3rd quarter. Renaissance Capital LLC now owns 84,166 shares of the company’s stock valued at $6,793,000 after acquiring an additional 17,866 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Tempus AI by 1,459.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company’s stock worth $8,174,000 after purchasing an additional 94,783 shares in the last quarter. Hussman Strategic Advisors Inc. acquired a new stake in Tempus AI during the 3rd quarter valued at $1,695,000. Vanguard Group Inc. raised its stake in Tempus AI by 22.1% during the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock valued at $762,032,000 after purchasing an additional 1,706,837 shares during the period. Finally, Krane Funds Advisors LLC lifted its holdings in shares of Tempus AI by 218.2% in the third quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company’s stock valued at $2,427,000 after purchasing an additional 19,358 shares in the last quarter. 24.22% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Beat-and-raise fundamentals — Tempus reported robust Q4 and full‑year 2025 results (strong revenue growth, narrower net loss, positive adjusted EBITDA progression) and issued 2026 guidance that targets revenue growth and a first full‑year adjusted EBITDA inflection, supporting a fundamental recovery case. Why Tempus AI (TEM) Is Down 7.5% After 2025 Results
• Positive Sentiment: Product & commercial catalysts — Launch of an HRD‑RNA oncology algorithm and a partnership with Median Technologies to expand lung cancer screening distribution broaden Tempus’s diagnostic pipeline and addressable market if adoption scales. Tempus AI Deepens Precision Oncology Role With New HRD And Lung Tools
• Positive Sentiment: Institutional support and rebound narrative — Several outlets highlight heavy institutional buying, improving unit economics and analyst upside scenarios, which could limit downside and set up a technical rebound if execution continues. Tempus AI Sold Off After a Beat—But the Rebound Case Is Building
• Neutral Sentiment: Investor event calendar — Management will present at the Morgan Stanley TMT conference (March 3); the fireside chat could provide additional color but is not a guaranteed catalyst. Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference
• Neutral Sentiment: Valuation updates — Some fair‑value and price‑target revisions trimmed upside modestly; analysts still show a range of bullish and cautious views, leaving the story sensitive to near‑term execution. How The Tempus AI (TEM) Investment Story Is Evolving With New Data And Valuation Views
• Negative Sentiment: Analyst downgrades and price‑target cuts — Recent analyst actions (including a notable downgrade reported 2/27 and several target cuts in the prior 24 hours) have intensified selling pressure and weakened sentiment despite the beat. Tempus AI (NASDAQ:TEM) Shares Down 7.4% After Analyst Downgrade
• Negative Sentiment: ESOP shelf registration and dilution risk — Tempus filed a US$343.38M ESOP‑related shelf registration; potential future share issuance tied to employee plans can pressure the stock if investors fear dilution. Why Tempus AI (TEM) Is Down 7.5% After 2025 Results
• Negative Sentiment: Execution, debt and market risk — High leverage, a volatile post‑IPO trading history, elevated beta and lingering execution/valuation concerns make the stock susceptible to outsized moves on negative headlines. Is It Time To Reassess Tempus AI (TEM) After Recent Share Price Weakness?

Tempus AI Trading Down 3.9%

TEM opened at $53.25 on Friday. The stock has a market capitalization of $9.47 billion, a PE ratio of -37.77 and a beta of 5.22. The company has a debt-to-equity ratio of 2.52, a quick ratio of 3.12 and a current ratio of 3.13. Tempus AI has a one year low of $36.22 and a one year high of $104.32. The business’s 50 day moving average price is $61.34 and its 200 day moving average price is $73.33.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.